{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:52:46Z","timestamp":1793170366595,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.2515\/therapie\/2010069","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T10:38:01Z","timestamp":1293014281000},"page":"533-541","source":"Crossref","is-referenced-by-count":16,"title":["Safety Review: Squalene and Thimerosal in Vaccines"],"prefix":"10.1016","volume":"65","author":[{"given":"Marc","family":"Montana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ducros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Terme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Vanelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Rathelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2010069_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0002-9343(87)90555-9","article-title":"Clinical manifestation and consequence of influenza","volume":"82","author":"Cate","year":"1987","journal-title":"Am J Med"},{"key":"10.2515\/therapie\/2010069_bb0010","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.1176062","article-title":"Pandemic potential of a strain of influenza A (H1N1): early findings","volume":"324","author":"Fraser","year":"2009","journal-title":"Science"},{"key":"10.2515\/therapie\/2010069_bb0015","unstructured":"World Health Organization. Pandemic H1N1 2009-Update 89, http:\/\/www.who.int\/csr\/don\/2010_02_26\/en\/index.html."},{"key":"10.2515\/therapie\/2010069_bb0020","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0264-410X(00)00499-0","article-title":"The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine","volume":"19","author":"Podda","year":"2001","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03324904","article-title":"Immunosenescence and vaccine failure in the elderly","volume":"21","author":"Grubeck-Loebenstein","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"10.2515\/therapie\/2010069_bb0030","first-page":"822","article-title":"Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function","volume":"92","author":"Phair","year":"1978","journal-title":"J Lab Clin Med"},{"key":"10.2515\/therapie\/2010069_bb0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jmv.1890250112","article-title":"Failure of influenza vaccination in the aged","volume":"25","author":"Keren","year":"1988","journal-title":"J Med Virol"},{"key":"10.2515\/therapie\/2010069_bb0040","unstructured":"Ford S, Clews G. DH director of immunisation tells nurses they have a \u2018duty\u2019 to have swine flu jab. Nursing Time.net, http:\/\/www.nursingtimes.net\/whats-new-in-nursing\/swine-flu\/dhdirector-of-immunisation-tells-nurses-they-have-a-dutyto-have-swine-flu-jab\/5005221.article"},{"key":"10.2515\/therapie\/2010069_bb0045","first-page":"3398","article-title":"Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys","volume":"339b","author":"Chor","year":"2009","journal-title":"BMJ"},{"key":"10.2515\/therapie\/2010069_bb0050","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.3390\/molecules14093286","article-title":"Squalene emulsions for parenteral vaccine and drug delivery","volume":"14","author":"Fox","year":"2009","journal-title":"Molecules"},{"key":"10.2515\/therapie\/2010069_bb0055","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/194479a0","article-title":"Detection and estimation of squalene in leaves","volume":"194","author":"Alam","year":"1962","journal-title":"Nature"},{"key":"10.2515\/therapie\/2010069_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/1097-458X(200101)39:1<29::AID-MRC796>3.0.CO;2-#","article-title":"NMR determination of site-specific deuterium distribution (SNIF-NMR) in squalene from different sources","volume":"39","author":"Deiana","year":"2001","journal-title":"Magn Reson Chem"},{"key":"10.2515\/therapie\/2010069_bb0070","first-page":"29","article-title":"Squalene and its potential clinical uses","volume":"4","author":"Kelly","year":"1999","journal-title":"Alter Med Rev"},{"key":"10.2515\/therapie\/2010069_bb0075","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1039\/b406854h","article-title":"Products and processes for a sustainable chemical industry: a review of achievements and prospects","volume":"6","author":"Jenck","year":"2004","journal-title":"Green Chem"},{"key":"10.2515\/therapie\/2010069_bb0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/meth.1999.0832","article-title":"Squalene and squalane emulsions as adjuvants","volume":"19","author":"Allison","year":"1999","journal-title":"Methods"},{"key":"10.2515\/therapie\/2010069_bb0085","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0264-410X(99)00263-7","article-title":"Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice","volume":"18","author":"Dupuis","year":"1999","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0090","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminium hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differenciation toward dendritic cells","volume":"180","author":"Seubert","year":"2008","journal-title":"J Immunol"},{"key":"10.2515\/therapie\/2010069_bb0095","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/cmice immunized with trivalent influenza vaccine containing MF59\u00ae oilemulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J Immunol"},{"key":"10.2515\/therapie\/2010069_bb0100","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.vaccine.2009.01.084","article-title":"Mechanism of action of licensed vaccine adjuvants","volume":"27","author":"Tritto","year":"2009","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0105","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus nonadjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000069172","article-title":"A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis","volume":"49","author":"Banzhoff","year":"2003","journal-title":"Gerontology"},{"key":"10.2515\/therapie\/2010069_bb0115","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1016\/j.vaccine.2007.02.045","article-title":"MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications","volume":"25","author":"Baldo","year":"2007","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0120","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/S0264-410X(03)00456-0","article-title":"Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults","volume":"21","author":"Frey","year":"2003","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/INF.0b013e31819d6394","article-title":"Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.2515\/therapie\/2010069_bb0130","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","article-title":"Safety and antigenicity of nonadjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza","volume":"357","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010069_bb0135","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","article-title":"Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly","volume":"17","author":"De Donato","year":"1999","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0264-410X(98)00185-6","article-title":"Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons","volume":"17","author":"Minutello","year":"1999","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0145","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1016\/S0264-410X(01)00060-3","article-title":"Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly","volume":"19","author":"Baldo","year":"2001","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1017919305501","article-title":"Increased immunogenicity of the MF59\u00ae-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects","volume":"17","author":"Gasparini","year":"2001","journal-title":"Eur J Epidemiol"},{"key":"10.2515\/therapie\/2010069_bb0155","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0264-410X(02)00401-2","article-title":"Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects","volume":"21","author":"Squarcione","year":"2003","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/5f2ae0fb-53f1-48c2-aa19-9114765ba029","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS One"},{"key":"10.2515\/therapie\/2010069_bb0165","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.vaccine.2009.11.077","article-title":"Exposure to MF59-adjuvanted influenza vaccines during pregnancy-A retrospective analysis","volume":"28","author":"Tsai","year":"2010","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0170","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1016\/j.vaccine.2009.07.102","article-title":"Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults","volume":"27","author":"Chu","year":"2009","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0175","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010069_bb0180","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","article-title":"Priming with AS03(A)-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0185","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"R\u00fcmke","year":"2008","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0190","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2009.12.014","article-title":"Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial","volume":"28","author":"Roman","year":"2010","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0195","first-page":"146","article-title":"Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3\u20139 years: a phase II study","volume":"12","author":"Ballester","year":"2008","journal-title":"IJID"},{"key":"10.2515\/therapie\/2010069_bb0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00430-009-0130-9","article-title":"Possible hidden hazards of mass vaccination against new influenza A\/H1N1: have the cardiovascular risks been adequately weighed?","volume":"198","author":"Bhakdi","year":"2009","journal-title":"Med Microbiol Immunol"},{"key":"10.2515\/therapie\/2010069_bb0205","series-title":"Inc. Panenzar\u00ae and Humenzar\u00ae Influenza A (H1N1) vaccines demonstrate robust immune response after one dose [media release]","author":"Pasteur","year":"2009"},{"key":"10.2515\/therapie\/2010069_bb0210","series-title":"Pharmacovigilance of A (H1N1) influenza vaccines","year":"2010"},{"key":"10.2515\/therapie\/2010069_bb0215","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jinorgbio.2009.05.019","article-title":"Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration","volume":"103","author":"Shaw","year":"2009","journal-title":"J Inorg Biochem"},{"key":"10.2515\/therapie\/2010069_bb0220","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0002-9440(10)65077-8","article-title":"The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats","volume":"156","author":"Carlson","year":"2000","journal-title":"American Journal of Pathology"},{"key":"10.2515\/therapie\/2010069_bb0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1365-2249.2002.01783.x","article-title":"The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes","volume":"127","author":"Holm","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.2515\/therapie\/2010069_bb0230","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barre syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010069_bb0235","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1001\/jama.292.20.2478","article-title":"Guillain-Barre syndrome following influenza vaccination","volume":"292","author":"Haber","year":"2004","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010069_bb0240","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1016\/j.vaccine.2007.03.053","article-title":"Guillain-Barre syndrome after vaccination in United States a report from the CDC\/FDA vaccine adverse event reporting system","volume":"25","author":"Souayah","year":"2007","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1086\/594124","article-title":"Guillain-Barre syndrome and influenza virus infection","volume":"48","author":"Sivadon-Tardy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2010069_bb0250","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pone.0000344","article-title":"Guillain-Barre syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database","volume":"2","author":"Tam","year":"2007","journal-title":"PLoS One"},{"key":"10.2515\/therapie\/2010069_bb0255","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and inflenzalike illness using the United Kingdom general practice Research database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.2515\/therapie\/2010069_bb0260","first-page":"162","article-title":"Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome","volume":"159","author":"Gherardi","year":"2003","journal-title":"Rev Neurol"},{"key":"10.2515\/therapie\/2010069_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/exmp.2002.2429","article-title":"Antibodies to squalene in recipients of anthrax vaccine","volume":"73","author":"Asa","year":"2002","journal-title":"Exp Mol Pathol"},{"key":"10.2515\/therapie\/2010069_bb0270","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/exmp.1999.2295","article-title":"Antibodies to squalene in Gulf War syndrome","volume":"68","author":"Asa","year":"2000","journal-title":"Exp Mol Pathol"},{"key":"10.2515\/therapie\/2010069_bb0275","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/exmp.2000.2315","volume":"68","author":"Asa","year":"2000","journal-title":"Reply Exp Mol Pathol"},{"key":"10.2515\/therapie\/2010069_bb0280","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.biopha.2004.04.009","article-title":"Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine","volume":"58","author":"Kuroda","year":"2004","journal-title":"Biomed Pharmacother"},{"key":"10.2515\/therapie\/2010069_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0896-8411(03)00083-0","article-title":"Induction of lupus autoantibodies by adjuvants","volume":"21","author":"Satoh","year":"2003","journal-title":"J Autoimmun"},{"key":"10.2515\/therapie\/2010069_bb0290","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-3083.1999.00463.x","article-title":"Identification of arthritogenic adjuvants of self and foreign origin","volume":"49","author":"Lorentzen","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.2515\/therapie\/2010069_bb0295","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0940-2993(99)80072-4","article-title":"The experimental squalene encephaloneuropathy in the rat","volume":"51","author":"Gajkowska","year":"1999","journal-title":"Exp Toxicol Pathol"},{"key":"10.2515\/therapie\/2010069_bb0300","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jpba.2006.04.009","article-title":"Enhancement of an analytical method for the determination of squalene in anthrax vaccine adsorbed formulations","volume":"42","author":"Spanggord","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"10.2515\/therapie\/2010069_bb0305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0731-7085(02)00009-2","article-title":"Development and application of an analytical method for the determination of squalene in formulations of anthrax vaccine adsorbed","volume":"29","author":"Spanggord","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"10.2515\/therapie\/2010069_bb0310","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/exmp.2000.2314","article-title":"Re: Antibodies to squalene in Gulf War Syndrome","volume":"68","author":"Alving","year":"2000","journal-title":"Exp Mol Pathol"},{"key":"10.2515\/therapie\/2010069_bb0315","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/CVI.00191-06","article-title":"Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene","volume":"13","author":"Del Giudice","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.2515\/therapie\/2010069_bb0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jim.2003.11.002","article-title":"Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice","volume":"286","author":"Matyas","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.2515\/therapie\/2010069_bb0325","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-1759(02)00180-1","article-title":"Induction and detection of antibodies to squalene. II. Optimization of the assay for murine antibodies","volume":"267","author":"Matyas","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.2515\/therapie\/2010069_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(00)00268-4","article-title":"Induction and detection of antibodies to squalene","volume":"245","author":"Matyas","year":"2000","journal-title":"J Immunol Methods"},{"key":"10.2515\/therapie\/2010069_bb0335","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1016\/j.vaccine.2009.03.091","article-title":"Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness","volume":"27","author":"Phillips","year":"2009","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2010069_bb0340","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Actualisation de l\u2019avis relatif aux recommandations sur les priorit\u00e9s sanitaires d\u2019utilisation des vaccins pand\u00e9miques dirig\u00e9s contre le virus grippal A(H1N1), http:\/\/www.hcsp.fr\/docspdf\/avisrapports\/hcspa20091002_H1N1.pdf"},{"key":"10.2515\/therapie\/2010069_bb0345","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1054\/mehy.2000.1281","article-title":"Autism: a novel form of mercury poisoning","volume":"56","author":"Bernard","year":"2001","journal-title":"Med Hypotheses"},{"key":"10.2515\/therapie\/2010069_bb0350","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/sj.mp.4001177","article-title":"The role of mercury in the pathogenesis of autism","volume":"7","author":"Bernard","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.2515\/therapie\/2010069_bb0355","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/153537020322800603","article-title":"Neurodevelopmental disorders after thimerosalcontaining vaccines: a brief communication","volume":"228","author":"Geier","year":"2003","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.2515\/therapie\/2010069_bb0360","first-page":"383","article-title":"A comprehensive review of mercury provoked autism","volume":"128","author":"Geier","year":"2008","journal-title":"Indian J Med Res"},{"key":"10.2515\/therapie\/2010069_bb0365","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0161-813X(01)00067-5","article-title":"Predicted mercury concentrations in hair from infant immunizations: cause for concern","volume":"22","author":"Redwood","year":"2001","journal-title":"Neurotoxicology"},{"key":"10.2515\/therapie\/2010069_bb0370","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1542\/peds.107.5.1147","article-title":"An assessment of thimerosal use in childhood vaccines","volume":"107","author":"Ball","year":"2001","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2010069_bb0375","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1542\/peds.2006-3363","article-title":"Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines","volume":"121","author":"Pichichero","year":"2008","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2010069_bb0380","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(02)11682-5","article-title":"Mercury concentrations and metabolism in infants receiving vaccines containing thimesoral: a descriptive study","volume":"360","author":"Pichichero","year":"2002","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010069_bb0385","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(02)11723-5","article-title":"Mercury in vaccines-reassuring news","volume":"360","author":"Henderson","year":"2002","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010069_bb0390","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa071434","article-title":"Early thimesoral exposure and neuropsychological outcomes at 7 and 10 years","volume":"357","author":"Thompson","year":"2007","journal-title":"N Eng J Med"},{"key":"10.2515\/therapie\/2010069_bb0395","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0749-3797(03)00113-2","article-title":"Autism and thimerosal-containing vaccines: lack of consistent evidence for an association","volume":"25","author":"Stehr-Green","year":"2003","journal-title":"Am J Prev Med"},{"key":"10.2515\/therapie\/2010069_bb0400","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.112.3.604","article-title":"Thimerosal and the occurrence of autism: negative ecological evidence from Danish populationbased data","volume":"112","author":"Madsen","year":"2003","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2010069_bb0405","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1542\/peds.2005-2993","article-title":"Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations","volume":"118","author":"Fombonne","year":"2006","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2010069_bb0410","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1542\/peds.112.5.1039","article-title":"Safety of thimesoral-containing vaccines: a two-phased study of computerized health maintenance organization databases","volume":"112","author":"Verstraeten","year":"2003","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2010069_bb0415","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.290.13.1763","article-title":"Association between thimerosalcontaining vaccine and autism","volume":"290","author":"Hviid","year":"2003","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010069_bb0420","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1542\/peds.2003-1176-L","article-title":"Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association","volume":"114","author":"Heron","year":"2004","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2010069_bb0425","series-title":"Report of the Institute of Medicine. Immunization safety review: vaccines and autism","author":"Immunization safety review committee","year":"2004"},{"key":"10.2515\/therapie\/2010069_bb0430","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.mehy.2003.11.033","article-title":"Thimerosal and autism? A plausible hypothesis that should not be dismissed","volume":"62","author":"Blaxill","year":"2004","journal-title":"Med Hypotheses"},{"key":"10.2515\/therapie\/2010069_bb0435","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mpd.2000.105133","article-title":"Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants","volume":"136","author":"Stajich","year":"2000","journal-title":"J Pediatr"},{"key":"10.2515\/therapie\/2010069_bb0440","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1126\/science.181.4096.230","article-title":"Methylmercury poisoning in Iraq","volume":"181","author":"Bakir","year":"1973","journal-title":"Science"},{"key":"10.2515\/therapie\/2010069_bb0445","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1542\/peds.104.3.568","article-title":"Joint Statement of the American Academy of Pediatrics (AAP) and the United States Public Health Services (USPHS) [editorial]","volume":"104","year":"1999","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2010069_bb0450","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2165\/00002018-200124080-00001","article-title":"Thiomersal in vaccines: is removal warranted?","volume":"24","author":"Clements","year":"2001","journal-title":"Drug Saf"},{"key":"10.2515\/therapie\/2010069_bb0455","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0536.1988.tb02809.x","article-title":"Thiomersal allergy and vaccination reactions","volume":"18","author":"Cox","year":"1988","journal-title":"Contact Dermatitis"},{"key":"10.2515\/therapie\/2010069_bb0460","first-page":"1501","article-title":"Mercury in vaccines","volume":"187","author":"Hessel","year":"2003","journal-title":"Bull Acad Natl Med"},{"key":"10.2515\/therapie\/2010069_bb0465","unstructured":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9. Le thiomersal, http:\/\/www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/52e910f9513961b1a638e4a2d4212ea1.pdf."}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T15:47:46Z","timestamp":1685893666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0040595716307235"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2010069","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}